Yu Baofa

Yu Baofa (Chinese: 于保法; pinyin: Yú Bǎofǎ; born in 1958) is a Chinese oncologist and researcher in intratumoral cancer therapy and drug development.[1] He is the Founder, CEO and Chairman of Baofa Cancer Hospital Network China in Jinan, Beijing and Dongping.[2] He also developed Ultra Minimum Incision Personalized Intra-Tumoral Chemo-Immuno (UMIPIC) Therapy.[3][4]

In this Chinese name, the family name is Yu.
Dr.

Yu Baofa
Born1958 (age 64–65)
Jinan, China
NationalityChinese
EducationBinzhou Medical College, Peking Union Medical College
OccupationOncologist
Medical career
ResearchIntratumoral Cancer Therapy
Notable worksUltra Minimum Incision Personalized Intra-Tumoral Chemo-Immuno (UMIPIC) Therapy.
Websitewww.baofatherapy.com

Early life and education

Yu was born in 1958 in Jinan, Shandong, China. During his childhood, the local doctors he saw in his village inspired him to become a physician in the future. He was educated in Binzhou Medical College. Four years later, he graduated and landed a job in the Shandong Tumor Research Institute and transferred to the China Academy of Medical Sciences for further studies in cancer.[1]

In 1984, his mother was diagnosed with esophageal cancer and later died. Soon after, his best friend's father died of cancer as well. These experiences motivated him to deepen his research of cancer.[1]

In 1985, Yu enrolled in Peking Union Medical College (tumour department) in Beijing to further his studies and received a master's degree of Medicine. After graduation, he worked at the China-Japan Friendship Hospital in Beijing for a year, before attending the School of Medicine of University of California, San Diego for doctoral studies.[1]

Career
  • In February 1990, Yu performed research on anti-cancer medicines and intratumoral therapy. It was at the time he researched on drug slow-release system therapy (SRST).[1]
  • In 1992, Yu joined the Salk Institute in La Jolla, California as Senior Associate Researcher for tumour and cancer genes. A year later, he was appointed as Associate Professor at the University of California, San Diego.[1]
  • In 1998, he returned to China and founded the TaiMei Baofa Cancer Hospital in Dongping, China.[1]
  • In 2003, Yu was elected as the deputy of the 10th National People's Congress.[1]
  • At present, he is the CEO of Immuno Oncology Systems (IOS) & Baofa Therapy Inc.[2]

Hospitals

Taimei Baofa Cancer Hospital was the first hospital established among three of Dr. Yu's hospitals. Since 1997, it has raised 38 million yuan (US$4.6 million). Yu also invited experts from Beijing and Jinan to offer training to his medical staff occasionally.[5]

His hospitals utilize various cancer treatments including surgery, radiotherapy, biological therapy, UMIPIC, as well as traditional Chinese medical treatments.[5]

Awards
  • 2006- China Youth Volunteer Action Contribution Award[6]
  • 2005- First overseas Chinese "Outstanding Entrepreneurship Award"[7]

Patents

Publications

References
  1. "Professor devoted to medical research and treatmentn". www.chinadaily.com.cn. Retrieved 3 March 2019.
  2. "Meet Dr. Baofa Yu". Baofa Immunotherapy, LLC. Retrieved 3 March 2019.
  3. Yu, Baofa; Lu, Yuanfei; Gao, Feng; Jing, Peng; Wei, Han; Zhang, Peicheng; Liu, Guoliang; Ru, Ning; Cui, Guanghui; Xu, Xinhai; Sun, Chenglin; Guan, Changjiang; Che, Yebing; Wu, Yingli; Ma, Zhenlu; Fu, Qiang; Liu, Jian; Wang, Huan-You (2015). "Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy". Lung Cancer: Targets and Therapy. 6: 1–11. doi:10.2147/LCTT.S70679. PMC 5217516. PMID 28210146.
  4. Gao, Feng; Jing, Peng; Liu, Jian; Lu, Yuanfei; Zhang, Peicheng; Han, Wei; Liu, Guoliang; Ru, Ning; Cui, Guanghui; Sun, Chenglin; Che, Yebing; Zhang, Huaming; Hu, Qnglong; Wang, Huan-You; Wu, Yingli; Guan, Changjiang; Fu, Qiang; Ma, Zhenlu; Yu, Baofa (2015). "Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy". Journal of Hepatocellular Carcinoma. 2: 57–68. doi:10.2147/JHC.S80756. PMC 4918285. PMID 27508195.
  5. "Hospital offers service to cancer patients | chinadaily.com.cn". www.chinadaily.com.cn. Retrieved 3 March 2019.
  6. "China Youth Volunteer Action Contribution Award - Shandong Baofa Oncotherapy Corporation Limited". www.baofayiliao.com. Retrieved 2019-03-06.
  7. "Professor Yu Baofa won the first overseas Chinese "Outstanding Entrepreneurship Award" - Shandong Baofa Oncotherapy Corporation Limited". www.baofayiliao.com. Retrieved 2019-03-06.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.